Table 1.

Summary of the data on clinical responses of lung cancers harboring E709X and G719X to EGFR-TKIs

Response to TKI
MutationsTKIsNCR/PRSD/PDNERR (%)PRef.
G719AGef/Erl23815350.83a
G719SGef/Erl52340a
G719A + S720F/L747S/S768I/L833V+V834C/L858R/L861Q/L861RGef/Erl1697560.76a
G719S + Q701L+I706T/L858R/L861QGef/Erl105550a
E709K + G719X/L858RGef/Erl431750.64a
E709A + G719X/L858RGef/Erl53260a
G719XAfatinib1814478(28)
G719XNeratinib430175(29)

Abbreviations: NE, not evaluable; Erl, erlotinib; Gef, gefitinib; RR, response rate.

  • aSummary of multiple literature, which is described in Supplementary Table S1. The clinical responses to gefitinib or erlotinib in tumors with the top two mutations at codons 709 and 719 were compared, respectively. Single and complex mutations were analyzed independently.